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Context: Isolated central congenital hypothyroidism (CCH) is rare and evades diagnosis on TSH-
based congenital hypothyroidism (CH) screening programs in the United Kingdom. Accordingly,
genetic ascertainment facilitates diagnosis and treatment of familial cases. Recognized causes
include TSH  subunit (TSHB) and Ig superfamily member 1 (IGSF1) mutations, with only two
previous reports of biallelic, highly disruptive mutations in the TRH receptor (TRHR) gene.
Case Description: A female infant presenting with prolonged neonatal jaundice was found to have
isolated CCH, with TSH of 2.2 mU/L (Reference range, 0.4–3.5) and free T4 of 7.9 pmol/L (0.61 ng/dL)
(Reference range, 10.7–21.8 pmol/L). Because TSHB or IGSF1 mutations are usually associated with
profound or X-linked CCH, TRHR was sequenced, and a homozygous mutation (p.P81R) was iden-
tified, substituting arginine for a highly conserved proline residue in transmembrane helix 2.
Functional studies demonstrated normal cell membrane expression and localization of the mutant
TRHR; however, its ability to bind radio-labelled TRH and signal via Gq was markedly impaired,
likely due to structural distortion of transmembrane helix 2.
Conclusions: Two previously reported biallelic, highly disruptive (nonsense; R17*, in-frame dele-
tion and single amino acid substitution; p.[S115-T117del; A118T]) TRHR mutations have been
associated with CCH; however, we describe the first deleterious, missense TRHR defect associated
with this phenotype. Importantly, the location of the mutated amino acid (proline 81) highlights
the functional importance of the second transmembrane helix in mediating hormone binding and
receptor activation. Future identification of other naturally occurring TRHR mutations will likely
offer important insights into the molecular basis of ligand binding and activation of TRHR, which
are still poorly understood. (J Clin Endocrinol Metab 101: 847–851, 2016)
Isolated central congenital hypothyroidism (CCH) oc-curs when there is inadequate TSH-mediated stimula-
tion of the thyroid gland. To date, genetic disorders af-
fecting TSH biosynthesis have been restricted to mutations
in three genes, namely TSHB, TRHR, and IGSF1 (1). TSH
is inappropriately normal or subnormal, precluding diag-
nosis on the UK TSH-based congenital hypothyroidism
(CH) screening program, and delayed initiation of treat-
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ment with T4 may compromise growth and neurological
development. Biallelic TRHR mutations have hitherto
been described in only two unrelated kindreds in which
three affected individuals exhibited CCH and absent TSH
and prolactin responses to exogenous TRH. In the first
kindred, one affected individual was compound heterozy-
gous for a paternally inherited nonsense mutation (R17*)
and a complex combination of mutations on the maternal
allele comprising an in-frame deletion (S115, I116, and
T117) with one amino acid substitution (p.A118T). In the
second kindred, two affected individuals were homozy-
gous for the R17* mutation (2, 3).
TRH receptor (TRHR) is a G protein-coupled plasma
membrane receptor (GPCR) belonging to the largest sub-
class (family A, rhodopsin-like 7 transmembrane domain
receptors). Hypothalamic TRH signaling via TRHR pri-
marily involves mobilization of intracellular calcium and
activation of protein kinase C through a Gq/11-dependent
pathway (4, 5). TRH both mediates transcriptional acti-
vation of target genes, eg, TSH -subunit (CGA) and
-subunit (TSHB), and exerts post-translational effects,
eg, conjugation, glycosylation, and secretion of the -sub-
unit/TSH heterodimer (TSH) in theanteriorpituitary (6).
Here, we describe a female Pakistani infant diagnosed
with CCH in the neonatal period. Parental consanguinity
favored recessive inheritance; thus, TRHR was the most
likely causative gene given her moderate biochemical de-
fect. Sequence analysis revealed a homozygous TRHR
missense mutation (p.P81R), and molecular studies con-
firmed impaired ligand binding and transcriptional acti-
vation by the mutant receptor.
Patient and Methods
All investigations were ethically approved and/or clinically in-
dicated, being undertaken with patient or parental consent.
Biochemical measurements
Hormone measurements were made using local automated
assays (Supplemental Data).
Molecular genetic studies
Sanger sequencing of TRHR, TSHB, and IGSF1 coding exons
was performed after PCR amplification of genomic DNA using
specific primers (Supplemental Data).
Molecular modeling
The TRHR structural model was generated by homology
modeling using the PHYRE server and MacPymol to generate
figures.
Construction of wild-type and mutant TRHR cDNA
expression vectors
Site-directed mutagenesis was used to generate P81R TRHR
cDNA (Supplemental Data). Wild-type (WT) and P81R TRHR
cDNAs were cloned into the eukaryotic expression vectors
pcDNA3 and pEGFP-N3 (Clontech) upstream of FLAG and
green fluorescent protein (GFP) epitope tags, respectively.
Transient transfection
HEK293 cells were transiently transfected using Lipo-
fectamine 2000 according to the manufacturer’s instructions and
cultured in DMEM supplemented with 10% FBS and 1% PSF on
glass coverslips for cell localization assays, 96-well plates for
functional assays, or 10-cm dishes for immunoprecipitation
assays.
Cell localization
HEK293 cells transfected with TRHR-GFP constructs (50
ng/coverslip) were incubated with CellMask Deep Red Plasma
Membrane Stain and DAPI nuclear stain (Life Technologies) and
analyzed using a Zeiss LSM 510 META confocal microscope,
and images were processed with ZEN software (Zeiss).
TSH promoter activation
HEK293 cells cotransfected with TRHR-FLAG constructs
(10 ng/well), TSH-LUC reporter (150 ng/well) (7), and internal
control plasmid BOS--galactosidase (30 ng/well) were incu-
bated for 24 hours with growth medium containing TRH (0–100
nM) before measurement of luciferase and -galactosidase
activity.
Gq signaling
TRHR signaling through Gq protein was monitored using a
secondary messenger inositol phosphate accumulation assay
adapted from a published protocol (Supplemental Data).
Radioligand binding
Receptor binding of [3H][3Me-His2]TRH was performed ac-
cording to an adaptation of a published protocol (Supplemental
Data).
Immunoprecipitation
HEK293 cells transfected with TRHR-FLAG constructs (10
g/dish) were lysed (RIPA buffer) after 24 hours, immunopre-
cipitated with anti-FLAG affinity gel (F3165; Sigma), and ana-
lyzed by Western blotting (AntiFlag, F3165, Sigma; -actin,
Ab8227, Abcam).
Results
Clinical and biochemical features
Our patient, the daughter of Pakistani parents who
were first cousins, was born at 38 weeks of gestation by
caesarean section due to placenta previa. She presented at
age 19 days with neonatal jaundice due to isolated hyper-
bilirubinemia with bilirubin 174 mol/L (10.2 ng/dL),
(Reference range (RR), 0–120 mol/L), for which she had
no identifiable risk factors. The jaundice resolved spon-
taneously; however, despite a normal neonatal screening
heel prick TSH (1 mU/L), she underwent further endocrine
evaluation that revealed CCH with TSH of 2.2 mU/L (RR,
848 Koulouri et al A Novel TRH Receptor Mutation J Clin Endocrinol Metab, March 2016, 101(3):847–851
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 12 May 2016. at 05:27 For personal use only. No other uses without permission. . All rights reserved.
0.4–3.5) and free T4 of 7.9 pmol/L (0.61 ng/dL) (RR,
10.7–21.8 pmol/L). Basal pituitary function was other-
wise normal: prolactin, 239 mU/L (11.3 ng/mL) (RR, 27–
540 mU/L); cortisol, 220 nmol/L (8 g/dL) (midday); and
IGF-1, 6.7 nmol/L (51.3 ng/mL) (RR, 2.6–17 nmol/L).
Pituitary magnetic resonance imaging was unremarkable.
Her birth weight was 2.81 kg (25th centile), and she grew
and developed normally before the initiation of levothy-
roxine treatment at 2 months of age. Currently aged 4.2
years, her growth and neurological development have re-
mained normal (height SDS, 0.27; weight SDS, 2.24;
age, 3.8 years). Her mother and brother were euthyroid
(Figure 1A); her father declined investigation.
Molecular genetic studies
TRHR sequencing revealed a homozygous single nu-
cleotide substitution (c.242CG) corresponding to a pro-
line to arginine change at codon 81 (p.P81R), which is
absent from normal genome datasets (dbSNP; Exome Ag-
gregation Consortium [ExAC], Cambridge, MA; http://
exac.broadinstitute.org, October 2015). Her mother and
brother were heterozygous and WT, respectively (Figure
1A).
Cellular localization
Although the P81R mutation occurs in transmembrane
helix 2 (TM2) of TRHR, the P81R and WT TRHR-GFP
fusion proteins demonstrated similar plasma membrane
expression (Figure 1B).
TRHR signaling
Transient transfection assays were used to interrogate:
1) transactivation of the TSH -subunit promoter region,
using a luciferase reporter construct; and 2) TRHR-cou-
pled Gq signaling by measuring accumulation of intra-
cellular inositol phosphate. In both assays, P81R was non-
functional compared with WT TRHR (Figure 1, C and D).
Ligand binding
A ligand binding assay using the high-affinity ligand
[3H][3Me-His2]TRH confirmed absent ligand binding by
P81R TRHR, with normal binding to the WT TRHR (Fig-
ure 1E).
Discussion
In two previously reported children with biallelic TRHR
mutations, associated clinical manifestations were mild
(growth retardation, delayed bone age) despite biochem-
ical evidence of CCH, with T4 levels ranging from 40 to
88% of the lower limit of normal. Some bioactive TSH
was produced, as evidenced by rising T4 levels after T4
withdrawal, and there was ostensibly no attributable neu-
rological deficit despite treatment initiation at ages 9 and
11 years, suggesting sufficient childhood thyroid hormone
production to prevent severe developmental delay. How-
ever, T4 replacement did improve growth and quality of
life in these individuals (2, 3). Although TRHR is ex-
pressed on lactotrophs and mediates prolactin secretion in
response to exogenous TRH, a female homozygote for
p.R17* TRHR underwent two pregnancies and lactated
normally, suggesting that TRHR is not obligatory for
these functions in humans (3).
Our patient exhibits a TRHR missense mutation,
which we presume to be homozygous because parental
consanguinity would favor an autosomal recessive mode
of inheritance and her mother is heterozygous. Unfortu-
nately, her father declined genetic or biochemical evalu-
ation, and thus we cannot exclude maternal isodisomy or
a paternal deletion involving TRHR. Biochemical and ra-
diological features in our patient (T4 levels 74% of the
lower limit of normal, detectable TSH, normal basal pro-
lactin, and normal pituitary magnetic resonance imaging)
are concordant with previous cases and contrast with the
profound hypothyroidism typically seen in children with
TSHB mutations. Our patient’s age (30 months) pre-
cluded cessation of T4 for TRH testing (2, 3).
The molecular mechanisms of TRH binding and TRHR
activation remain poorly understood (8, 9). P81 has no
known direct role in TRH binding but underlies a proline
kink in TM2, which is conserved in 80% of GPCRs (Sup-
plemental Figure 1). This is thought to influence ligand
binding and signal transduction via an underlying hydro-
gen bond network, although its specific role in individual
GPCRs may depend on the surrounding amino acids; mu-
tation to alanine in CCR5 and AT1 receptors also results
in impaired receptor activation (9). Our data support a
critical functional role of P81 for ligand binding and thus
receptor activation. We hypothesize that the P81R muta-
tion alters the morphology of the proline kink in TM2,
thus potentially affecting the positioning of TM1 and the
extracellular loops and thereby altering the surface bind-
ing pocket (Figure 1F). Additional mutagenesis experi-
ments are required to exclude an independent role of P81
in TRHR signal transduction.
This is the first report of a naturally occurring homozy-
gous TRHR missense mutation, with similar clinical fea-
tures to previous TRHR mutation cases. Despite the rel-
atively mild reported sequelae of CCH due to TRHR
mutations, T4 replacement ameliorates growth retarda-
tion and improves quality of life; additionally, detailed
neuropsychological assessment (not undertaken in pub-
lished cases) could plausibly delineate subtle neurological
benefits (2, 3). Because these patients evade diagnosis in
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Figure 1. A, Central hypothyroidism segregates with homozygosity for the TRHR P81R mutation. Family pedigree showing the following genotypes: white, WT
allele; black, mutant allele; black/white, heterozygous, with bars denoting individuals who have been genotyped. Biochemistry is tabulated at bottom of panel.
NA, not available. B, WT and P81R TRHR both display similar plasma membrane localization. HEK293 cells were transfected with GFP, or GFP-tagged WT, or
P81R TRHR. Nuclei (blue), plasma membrane (red), and GFP fusion (green) were visualized by immunofluorescence, and a composite merged image was
generated. C, P81R mutant TRHR is unable to mediate ligand-dependent transactivation. HEK293 cells were transfected with empty vector (pcDNA), or FLAG-
tagged WT, or P81R TRHR, together with the TRH-responsive TSH-TKLUC reporter in an assay of TRH-dependent transactivation. BOS--galactosidase was used
as an internal control. Data shown are normalized to maximal reporter gene activation with empty vector and represent the mean and SEM of at least 10
independent experiments. D, TRHR signaling via the Gq-regulated cascade is impaired by the P81R mutation. HEK293 cells were transfected with WT, P81R,
and empty (pcDNA) expression vectors and stimulated with increasing concentrations of TRH. TRHR signaling via the Gq-regulated cascade was assessed by
measuring accumulation of radio-labeled inositol monophosphate (IP-1) in the presence of Li2, inhibiting its further dephosphorylation. IP-1 was detected with
scintillation proximity assay beads with selective affinity for this secondary messenger. Data shown are normalized to maximal WT response to agonist stimulation
and represent the mean and SEM of three independent experiments. E, Binding of TRH to P81R TRHR is markedly impaired. HEK293 cells were transfected with
either empty vector (pcDNA), WT, or P81R TRHR and were incubated with increasing amounts of [3H][3Me-His2]TRH for 2 hours. A Western blot (inset) from
immunoprecipitated samples confirmed expression of both WT and P81R TRHR. CPM, counts per minute. F, Molecular modeling of TRHR showing the position
of P81 in TM2. The left panel shows TRHR positioned in the cell membrane. Amino acids from the surface ligand pocket are shown in cyan, and those of the
main ligand binding cavity are shown in orange. Superimposed in pink is the position of TM2 containing the P81R mutation and in purple the position of TM1
when the mutation is present. The right panel shows a superimposition of WT (green) and mutant (pink) TM2 models, with the position of P81R identified, which
is predicted to bring about a change in helix structure.
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countries such as the United Kingdom that rely on a TSH-
based CH screening program, genetic ascertainment is
crucial in enabling early detection and treatment. Alter-
natively, inclusion of T4 measurement in the neonatal CH
screening protocol (eg, in The Netherlands) enables early
diagnosis of CCH, including cases with life-threatening
additional pituitary hormone deficiencies. Identification
of novel TRHR point mutations in isolated CCH cases
may provide further molecular insights into TRHR
function.
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